{"id":"W4362522571","doi":"10.1038/s41591-023-02297-5","title":"Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Ignyta; Y-mAbs Therapeutics; Varian Medical Systems; St. Baldrick's Foundation; Pfizer; Actuate Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; Alex's Lemonade Stand Foundation for Childhood Cancer; V Foundation for Cancer Research","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neuroblastoma; Chemotherapy; Cyclophosphamide; Adverse effect; Clinical trial; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004623964,0.0004129912,0.0008899053,0.0007854794,0.00008454334,0.0000143633,0.0002057635,0.0003412119,0.0002431131],"category_scores_gemma":[0.001178785,0.0002294133,0.00007964047,0.002076312,0.0002599412,0.0001143541,0.00004414692,0.001701925,0.000122817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001298925,"about_ca_system_score_gemma":0.0003279898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004778782,"about_ca_topic_score_gemma":0.0001921792,"domain_scores_codex":[0.9965432,0.0001511704,0.000579724,0.0007626213,0.001246954,0.0007163691],"domain_scores_gemma":[0.9979943,0.000493472,0.0001857186,0.0006852889,0.0001664623,0.0004747624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9110656,0.002387954,0.001527435,0.0001409629,0.0002720504,0.01105764,0.0009882469,0.000005467662,0.02105682,0.00002107396,0.03639854,0.01507818],"study_design_scores_gemma":[0.8644689,0.05516335,0.01021664,0.001078299,0.0001512513,0.000341573,0.0002070364,0.0008895263,0.004934637,0.00003114353,0.06217933,0.0003383081],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796699,0.00009833001,0.000006900922,0.01292162,0.0004330181,0.002315057,0.00003180937,0.0003374519,0.004185859],"genre_scores_gemma":[0.9892125,0.0002297987,0.0002054156,0.001661282,0.0009047232,0.0001138866,0.0002572928,0.0001006264,0.007314519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05277539,"threshold_uncertainty_score":0.9355202,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03487887887345568,"score_gpt":0.3942430159057496,"score_spread":0.3593641370322939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}